Dimensional Fund Advisors LP Boosts Holdings in Bausch + Lomb Co. (NYSE:BLCO)

Dimensional Fund Advisors LP boosted its stake in Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 66.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 109,619 shares of the company's stock after buying an additional 43,740 shares during the period. Dimensional Fund Advisors LP's holdings in Bausch + Lomb were worth $1,979,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Barclays PLC purchased a new stake in shares of Bausch + Lomb during the third quarter worth approximately $5,797,000. Raymond James Financial Inc. purchased a new stake in shares of Bausch + Lomb during the fourth quarter worth approximately $2,844,000. Renaissance Technologies LLC purchased a new stake in shares of Bausch + Lomb during the fourth quarter worth approximately $372,000. Ellsworth Advisors LLC acquired a new position in Bausch + Lomb in the fourth quarter valued at approximately $665,000. Finally, Renaissance Capital LLC boosted its holdings in Bausch + Lomb by 116.2% in the fourth quarter. Renaissance Capital LLC now owns 94,182 shares of the company's stock valued at $1,701,000 after purchasing an additional 50,622 shares in the last quarter. 11.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Wells Fargo & Company lowered their price target on Bausch + Lomb from $15.00 to $12.00 and set an "equal weight" rating for the company in a report on Thursday, May 1st. Evercore ISI decreased their price objective on Bausch + Lomb from $19.00 to $15.50 and set an "outperform" rating for the company in a report on Thursday, May 1st. Royal Bank of Canada cut their price target on Bausch + Lomb from $18.00 to $17.00 and set an "outperform" rating for the company in a research note on Friday, April 4th. Bank of America cut their price target on Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating for the company in a research note on Thursday, February 20th. Finally, Needham & Company LLC restated a "hold" rating on shares of Bausch + Lomb in a research note on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $15.50.

Bausch + Lomb Price Performance

NYSE:BLCO traded down $0.07 during trading hours on Tuesday, hitting $11.71. The company's stock had a trading volume of 5,425 shares, compared to its average volume of 657,361. The business's 50-day moving average is $12.96 and its two-hundred day moving average is $16.17. The company has a market capitalization of $4.14 billion, a PE ratio of -12.90, a PEG ratio of 0.85 and a beta of 0.58. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.60. Bausch + Lomb Co. has a 52-week low of $10.45 and a 52-week high of $21.69.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.10). The firm had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.15 billion. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The company's quarterly revenue was up 3.5% compared to the same quarter last year. During the same period last year, the firm earned $0.07 EPS. As a group, research analysts anticipate that Bausch + Lomb Co. will post 0.74 EPS for the current fiscal year.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.